OREANDA-NEWS. July 15, 2014. The Federal Antimonopoly Service (FAS Russia) found that a former Director of the Department of the Ministry of Health Care and Social Development for Developing the Pharmaceutical Market and the Market of Medical Equipment had committed an administrative violation and fined the violator 15,000 RUB.

The Ministry violated the law by omissions in considering the issue of including “Apidra” (“Insulin Glulisine” International Non-Proprietary Name) in the List of drugs purchased with budgetary funds. FAS established that the insulin producer repeatedly asked the Ministry to include insulin in the List, but the drug was not included in the List.

As a result, access of the patients suffering from diabetes to the medicine was unreasonably restricted.

“In 2012, the Ministry of Health Care and Social Development was reorganized. Many officials were dismissed from public service. It took FAS over five months to find the official responsible in violating the antimonopoly law. By this investigation, FAS once again has confirmed that the most important in an administrative sanction for violating the antimonopoly law is not the size of a fine rather than inevitability of holding a violator liable without respect of persons”, commented Deputy Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev.